Chiu, Brian C.-H. http://orcid.org/0000-0001-8979-7244
Chen, Chang
You, Qiancheng http://orcid.org/0000-0002-6996-4196
Chiu, Rudyard
Venkataraman, Girish http://orcid.org/0000-0002-8674-2608
Zeng, Chang http://orcid.org/0000-0003-3520-3724
Zhang, Zhou http://orcid.org/0000-0002-9639-052X
Cui, Xiaolong http://orcid.org/0000-0002-1345-2271
Smith, Sonali M.
He, Chuan http://orcid.org/0000-0003-4319-7424
Zhang, Wei http://orcid.org/0000-0003-0875-263X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities (R21 MD011439, R21 MD011439)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA223662, R01 CA223662)
U.S. Department of Health & Human Services | NIH | National Institute on Minority Health and Health Disparities
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 24 September 2020
Accepted: 12 January 2021
First Online: 11 February 2021
Competing interests
: C.H. and W.Z. are shareholders of Shanghai Epican Genetech Co., Ltd, which holds a license of the 5hmC-Seal technique from the University of Chicago for clinical applications. C.H. is the founder of Accent Therapeutics, Inc. and a member of its scientific advisory board. The remaining authors declare no conflict of interests.